Dr. Chiang on Immunotherapy in Patient Populations for Lung Cancer

Anne Chiang, MD, PhD
Published: Monday, Feb 06, 2017



Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Not all patients are going to respond to immunotherapy, explains Chiang. Right now, the patient population that has a tumor proportion score of greater than 50% will likely experience a greater benefit with immunotherapy.

For those in the 1% to 49% range, we are not sure what the right answer is, says Chiang. It is important to conduct further clinical trials in that patient population.
 


Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses immunotherapy in specific patient populations with lung cancer.

Not all patients are going to respond to immunotherapy, explains Chiang. Right now, the patient population that has a tumor proportion score of greater than 50% will likely experience a greater benefit with immunotherapy.

For those in the 1% to 49% range, we are not sure what the right answer is, says Chiang. It is important to conduct further clinical trials in that patient population.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x